- Home
- DHF vs PROF Comparison
DHF vs PROF Comparison
Compare DHF & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DHF | PROF |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.7M | 199.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DHF | PROF |
|---|---|---|
| Price | $2.48 | $7.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 451.1K | 88.7K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 7.65% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,297,000.00 |
| Revenue This Year | N/A | $64.23 |
| Revenue Next Year | N/A | $113.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 67.94 |
| 52 Week Low | $2.06 | $3.76 |
| 52 Week High | $2.39 | $7.99 |
Technical Indicators
Market Signals| Indicator | DHF | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 39.92 | 64.54 |
| Support Level | $2.49 | $7.19 |
| Resistance Level | $2.55 | $7.95 |
| Average True Range (ATR) | 0.02 | 0.41 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 22.22 | 83.87 |
Price Performance
Historical ComparisonAbout DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.